Although excluding individuals with reported diagnoses of autoimmune diseases of ulcerative colitis, Crohn’s disease, or rheumatoid arthritis or removal of those with positive biomarkers for rheumatoid arthritis (anti-CCP3, RF-IgA, and RF-IgM) did not significantly change the risk of NHL or DLBCL, we did not have data for all autoimmune diseases, medications for autoimmune diseases, or immunosuppressive treatment. This evidence concerns the gene CD79A and diffuse large B-cell lymphoma.